NEW YORK (GenomeWeb News) – Protein Discovery and New Objective will co-market each other's proteomics technologies and will develop new products under a new agreement, Protein Discovery said today.

The marketing agreement covers Protein Discovery's GelFree 8100 Fractionation System and New Objectives' PicoFrit nanobore chromatography columns and Digital PicoView nanospray sources.

Protein Discovery said that the combined technologies will give researchers top-down protein analysis with an integrated, standardized workflow for mass spectrometry projects.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.